NASDAQ: FLGCFlora Growth Corp Stock
$0.69-0.01 (-1.43%)
Updated Jul 11, 2025
FLGC Price
$0.69
Fair Value Price
N/A
Market Cap
$15.46M
52 Week Low
$0.42
52 Week High
$2.11
P/E
-0.7x
P/B
3.25x
P/S
0.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$53.26M
Earnings
-$13.32M
Gross Margin
21.7%
Operating Margin
-25.05%
Profit Margin
-25%
Debt to Equity
3.71
Operating Cash Flow
-$6M
Beta
1.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FLGC Overview
Flora Growth Corp. offers medicinal cannabis and medicinal cannabis derivative products to pharmacies, medical clinics, and cosmetic companies in the U.S. and internationally. Flora Growth sells its products under the JustCBD, Vessel, Mind Naturals, Mambe, Stardog, Tonino Lamborghini, and Kalaya brands. Flora Growth was incorporated in 2019 and is headquartered in Toronto, Ontario, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FLGC's potential to beat the market
- FLGC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
FLGC
RankedUnranked of 61
RankedUnranked of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $30.80 | A | |
| $3.00 | A | |
| $15.47 | A |
Be the first to know about important FLGC news, forecast changes, insider trades & much more!
FLGC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FLGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FLGC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FLGC is poor value based on its book value relative to its share price (3.25x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.2x)
P/B vs Industry Valuation
FLGC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FLGC due diligence checks available for Premium users.
Valuation
FLGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.7x
Industry
-18.61x
Market
30.99x
FLGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.25x
Industry
2.2x
FLGC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FLGC's financial health
Profit margin
Revenue
$11.8M
Net Income
-$758.0k
Profit Margin
-6.4%
FLGC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FLGC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.4M
Liabilities
$17.6M
Debt to equity
3.71
FLGC's short-term assets ($13.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FLGC's short-term assets ($13.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FLGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$437.0k
Financing
$0.0
FLGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FLGC vs Pharmaceutical Stocks
Flora Growth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.